BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. Journal of Crohn's and Colitis 2012;6:143-53. [DOI: 10.1016/j.crohns.2011.07.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043. [PMID: 32523620 DOI: 10.1177/1756284820915043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflamm Bowel Dis 2019;25:1357-66. [PMID: 30776076 DOI: 10.1093/ibd/izz012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sagar R, Lenti MV, Clark T, Rafferty HJ, Gracie DJ, Ford AC, O'Connor A, Ahmad T, Hamlin PJ, Selinger CP. Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflamm Intest Dis 2021;6:132-9. [PMID: 34722643 DOI: 10.1159/000515593] [Reference Citation Analysis]
4 Nagata Y, Fujimoto M, Nakamura K, Isoyama N, Matsumura M, Fujikawa K, Uchiyama K, Takaki E, Takii R, Nakai A, Matsuyama H. Anti-TNF-α Agent Infliximab and Splenectomy Are Protective Against Renal Ischemia-Reperfusion Injury. Transplantation 2016;100:1675-82. [PMID: 27163536 DOI: 10.1097/TP.0000000000001222] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 3.4] [Reference Citation Analysis]
5 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
6 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 117] [Article Influence: 28.8] [Reference Citation Analysis]
7 Ye C, Zhu S, Yuan J. Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease. Front Immunol 2022;13:871312. [DOI: 10.3389/fimmu.2022.871312] [Reference Citation Analysis]
8 Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. J Gastroenterol Hepatol 2018;33:1031-8. [PMID: 29087616 DOI: 10.1111/jgh.14034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
9 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014;7:359-67. [PMID: 25258548 DOI: 10.2147/CEG.S45297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
10 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Reference Citation Analysis]
11 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
12 Giese-kim N, Wu M, Dehghan M, Sceats LA, Park K. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Am J Gastroenterol 2020;115:1698-706. [DOI: 10.14309/ajg.0000000000000750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ye XQ, Cai J, Yu Q, Cao XC, Chen Y, Rao MX, Chen BL, He Y, Zeng ZR, Chen H, Lin YM, Cao Q, Chen MH, Zhang SH. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterol Rep (Oxf) 2021;9:329-38. [PMID: 34567565 DOI: 10.1093/gastro/goaa069] [Reference Citation Analysis]
14 Con D, Parthasarathy N, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley DJ, Sparrow MP, Gibson PR, van Langenberg DR, Vasudevan A. Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease.J Crohns Colitis. 2021;15:583-593. [PMID: 32949458 DOI: 10.1093/ecco-jcc/jjaa194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397-1407. [PMID: 22519466 DOI: 10.1111/j.1365-2036.2012.05100.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
16 Turner D, Lev-tzion R. Understanding Infliximab in Crohn’s Disease: The Long-Term Outcomes. Dig Dis Sci 2013;58:604-7. [DOI: 10.1007/s10620-012-2504-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
17 Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol 2020;55:1146-56. [PMID: 32780604 DOI: 10.1080/00365521.2020.1803396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
19 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 13.5] [Reference Citation Analysis]
21 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
22 Nuti F, Viola F, Civitelli F, Alessandri C, Aloi M, Dilillo A, Del Giudice E, Cucchiara S. Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center. Journal of Pediatric Gastroenterology & Nutrition 2014;58:582-7. [DOI: 10.1097/mpg.0000000000000276] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 2.9] [Reference Citation Analysis]
23 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
24 Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf 2017;16:303-17. [PMID: 27922765 DOI: 10.1080/14740338.2017.1269169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
25 Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T. Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res 2019;17:94-106. [PMID: 30508475 DOI: 10.5217/ir.2018.00048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Buisson A, Hordonneau C, Goutte M, Scanzi J, Goutorbe F, Klotz T, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease. Digestive and Liver Disease 2016;48:260-6. [DOI: 10.1016/j.dld.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
27 Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Choi GK, Collins SD, Greer DP, Warren L, Dowson G, Clark T, Hamlin PJ, Ford AC. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. J Crohns Colitis 2014;8:375-83. [PMID: 24129316 DOI: 10.1016/j.crohns.2013.09.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
29 Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. Front Immunol 2021;12:646673. [PMID: 34367126 DOI: 10.3389/fimmu.2021.646673] [Reference Citation Analysis]
30 Pinto-Lopes P, Afonso J, Pinto-Lopes R, Rocha C, Lago P, Gonçalves R, Tavares De Sousa H, Macedo G, Camila Dias C, Magro F. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2020;26:1707-1719. [PMID: 31912883 DOI: 10.1093/ibd/izz319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Agrawal M, Petralia F, Tepler A, Durbin L, Reinisch W, Colombel JF, Shah SC. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflamm Bowel Dis 2022:izac067. [PMID: 35366313 DOI: 10.1093/ibd/izac067] [Reference Citation Analysis]
32 Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall HU, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S, Bergquist A; International PSC Study Group. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2020;18:2295-2304.e2. [PMID: 32068151 DOI: 10.1016/j.cgh.2020.02.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Selinger CP, Lenti MV, Clark T, Rafferty H, Gracie D, Ford AC, Oʼconnor A, Ahmad T, Hamlin PJ. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:2083-8. [DOI: 10.1097/mib.0000000000001258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
34 Preda C, Fulger L, Gheorghe L, Gheorghe C, Goldis A, Trifan A, Tantau M, Tantau A, Negreanu L, Manuc M, Cijevschi-Prelipcean C, Iacob R, Tieranu C, Meianu C, Diculescu M. Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study. Curr Health Sci J 2016;42:115-24. [PMID: 30568821 DOI: 10.12865/CHSJ.42.02.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Flamant M, Rigaill J, Paul S, Roblin X. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. Drugs 2017;77:1057-68. [DOI: 10.1007/s40265-017-0755-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
36 Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol 2019;12:1756284819858052. [PMID: 31258621 DOI: 10.1177/1756284819858052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
37 Chavannes M, Martinez-vinson C, Hart L, Kaniki N, Chao C, Lawrence S, Jacobson K, Hugot J, Viala J, Deslandres C, Jantchou P, Seidman EG. Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study. Journal of Crohn's and Colitis 2019;13:578-84. [DOI: 10.1093/ecco-jcc/jjy206] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
38 Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:295-300. [DOI: 10.1080/13543784.2018.1442433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
39 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Reference Citation Analysis]
40 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
41 Yueying C, Jing F, Tian Y, Yuqi Q, Jun S. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients. Biomed Pharmacother 2021;142:112076. [PMID: 34449314 DOI: 10.1016/j.biopha.2021.112076] [Reference Citation Analysis]
42 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341-353. [PMID: 30824404 DOI: 10.1016/s2468-1253(19)30012-3] [Cited by in Crossref: 167] [Cited by in F6Publishing: 61] [Article Influence: 55.7] [Reference Citation Analysis]
44 Mohagheghi Darehranj S, Alatab S, Vahedi H, Sadeghi A, Sima A, Malekzadeh M, Anoshiravani A, Fakheri H, Ebrahimi Daryani N, Mousavi A, Mansour-Ghanaei F, Zahedi MJ, Malekzadeh R. Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. Middle East J Dig Dis 2020;12:12-8. [PMID: 32082516 DOI: 10.15171/mejdd.2020.158] [Reference Citation Analysis]
45 Yang LS, Alex G, Catto-Smith AG. The use of biologic agents in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2012;24:609-614. [PMID: 22828183 DOI: 10.1097/mop.0b013e3283574154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
46 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
47 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
48 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
49 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
50 Kansen HM, van Rheenen PF, Houwen RHJ, Tjon A Ten W, Damen GM, Kindermann A, Escher JC, Wolters VM; Kids with Crohnʼs, Colitis (KiCC) Working Group for Collaborative Paediatric IBD Research in the Netherlands. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators. J Pediatr Gastroenterol Nutr 2017;65:425-9. [PMID: 28945207 DOI: 10.1097/MPG.0000000000001551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
51 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
52 Chen Y, Li H, Feng J, Suo S, Feng Q, Shen J. A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn's Disease. J Inflamm Res 2021;14:2731-40. [PMID: 34194236 DOI: 10.2147/JIR.S314912] [Reference Citation Analysis]
53 Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039-46. [PMID: 28876147 DOI: 10.1080/17425255.2017.1377180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
54 Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018;11:1756283X17745029. [PMID: 29383027 DOI: 10.1177/1756283X17745029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
55 Ginard D, Khorrami S, Pérez-Carazo L, Tavío-Hernández E, López-Sanromán A, García-Alvarado M, Muñoz F, Ibáñez-Samaniego L, Marín-Jiménez I, Guevara J, Casellas F. [Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study]. Gastroenterol Hepatol 2016;39:369-76. [PMID: 27005800 DOI: 10.1016/j.gastrohep.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:38-47. [PMID: 33850838 DOI: 10.1159/000511296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Moroi R, Shiga H, Endo K, Yamamoto K, Kuroha M, Kanazawa Y, Kakuta Y, Kinouchi Y, Masamune A. Long-Term Prognosis of Japanese Patients with Crohn's Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies. Inflamm Intest Dis 2020;5:11-9. [PMID: 32232050 DOI: 10.1159/000504803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Ben-shatach Z, Ziv-baran T, Fudim E, Yavzori M, Picard O, Levartovsky A, Selinger L, Weiss B, Kopylov U, Eliakim R, Ungar B. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therap Adv Gastroenterol 2022;15:175628482210833. [DOI: 10.1177/17562848221083395] [Reference Citation Analysis]
60 Carman N, Mack DR, Benchimol EI. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0623-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
61 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 216] [Article Influence: 39.3] [Reference Citation Analysis]
62 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Reference Citation Analysis]
63 Tighe D, Smith S, O'Connor A, Breslin N, Ryan B, McNamara D. Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center. JGH Open 2017;1:4-10. [PMID: 30483525 DOI: 10.1002/jgh3.12000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
64 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 156] [Cited by in F6Publishing: 136] [Article Influence: 22.3] [Reference Citation Analysis]
65 Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR. Factors Associated with Durable Response to Infliximab in Crohnʼs Disease 5 Years and Beyond: A Multicenter International Cohort. Inflammatory Bowel Diseases 2015;21:60-70. [DOI: 10.1097/mib.0000000000000225] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
66 Varma P, Rajadurai AS, Holt DQ, Devonshire DA, Desmond CP, Swan MP, Nathan D, Shelton ET, Prideaux L, Sorrell C, Rusli F, Crantock LRF, Dev A, Ratnam DT, Pianko S, Moore GT. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Intern Med J 2019;49:753-60. [PMID: 30381884 DOI: 10.1111/imj.14150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 470] [Article Influence: 72.5] [Reference Citation Analysis]
68 Lima CCG, Queiroz NSF, Sobrado CW, Silva GLR, Nahas SC. CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2020;57:323-32. [PMID: 33027484 DOI: 10.1590/S0004-2803.202000000-59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Kim SE. [How Should We Do Different Approach to Treat Inflammatory Bowel Disease by Gender Difference?]. Korean J Gastroenterol 2021;77:241-7. [PMID: 34035202 DOI: 10.4166/kjg.2021.064] [Reference Citation Analysis]
70 Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818801244. [PMID: 30344642 DOI: 10.1177/1756284818801244] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
71 Szabó D, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh Á, Veres G. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease. Journal of Crohn's and Colitis 2014;8:747-55. [DOI: 10.1016/j.crohns.2013.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
72 Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]